Study of blood and tissue in small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at blood and tissue samples from people with small cell lung cancer that has returned. The goal is to learn more about the cancer and how to better treat it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You need a confirmed diagnosis of small cell lung cancer or another neuroendocrine cancer.
- Your cancer must have come back (relapsed), and you plan to receive a treatment called a DLL3 bispecific T cell engager (a type of immunotherapy).
- You must be willing to give blood samples and have tissue biopsies taken during the study.
- You must be able to make your own decisions and give informed consent. People who are incarcerated or have certain cognitive impairments cannot participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with small cell lung cancer who receive radiation therapy combined with other treatments. Researchers will track how well the treatment works and how patients respond over time to help improve future care.
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
This trial collects blood and tumor samples from people newly diagnosed with small cell lung cancer to study how genetic markers can predict treatment success and monitor disease over time.
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
This study collects tissue (and follows patients over time) to better understand the natural course of several types of chest cancers. It may help researchers learn which tests and treatments work best in different cancer types.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.